Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673
Malcolm A. Smith, Oliver A. Hampton, C. Patrick Reynolds, Min H. Kang, John M. Maris, Richard Gorlick, E. Anders Kolb, Richard Lock, Hernan Carol, Stephen T. Keir, Jianrong Wu, Raushan T. Kurmasheva, David A. Wheeler, Peter J. Houghton
Research output: Contribution to journal › Article › peer-review
Dive into the research topics of 'Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673'. Together they form a unique fingerprint.